Invention Grant
- Patent Title: Protective immunity enhanced
-
Application No.: US17273801Application Date: 2019-09-05
-
Publication No.: US11975061B2Publication Date: 2024-05-07
- Inventor: Roy Curtiss, III
- Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
- Applicant Address: US FL Gainesville
- Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
- Current Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
- Current Assignee Address: US FL Gainesville
- Agency: WOLTER, VAN DYKE, DAVIS, PLLC
- Agent Timothy H. Van Dyke
- International Application: PCT/US2019/049825 2019.09.05
- International Announcement: WO2020/051381A 2020.03.12
- Date entered country: 2021-03-05
- Main IPC: A23K10/16
- IPC: A23K10/16 ; A61K39/02 ; A61K39/00

Abstract:
Bacterial pathogens have evolved means to succeed as pathogens by infecting without recognition by receptors triggering innate immunity, by suppressing induction of immunity and by inducing immune responses to antigens that confer no protectives immunity. Embodiments described herein circumvent these abilities in Salmonella so as to provide a vector system that induces maximal protective immune responses. Another major problem in using live attenuated bacterial vaccine vectors is the accumulation of attenuating mutations that confer a virulence and safety but which decrease the ability of the vaccine to invade cells in the MALT to colonize and persist in internal effector lymphoid tissues. The embodiments disclosed herein solve this problem in multiple ways by using regulated delayed in vivo shut off of virulence genes, regulated delayed synthesis of recombinant protective antigens and regulated delayed lysis in vivo to confer biological containment with no persistence of vaccine cells and no survival if excreted.
Public/Granted literature
- US20220023408A1 PROTECTIVE IMMUNITY ENHANCED SALMONELLA VACCINE (PIESV) AGAINST BRUCELLA SPP. Public/Granted day:2022-01-27
Information query